REGENERON PHARMACEUTICALS, INC. (REGN) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $1.99B; Short-term DebtUSD (m); Convertible Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m).
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $1.99B; Short-term DebtUSD (m); Convertible Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $1.99B; Short-term DebtUSD (m); Convertible Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m).
- 2025-09-30: Long-term Debt, Excluding Current MaturitiesUSD $1.99B; Short-term DebtUSD (m); Convertible Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m).
REGENERON PHARMACEUTICALS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Short-term Debt USD | Convertible Notes Payable, Current USD | Long-term Line of Credit USD | Notes Payable USD | Debt Instrument, Face Amount USD | Long-term Debt, Fair Value USD | Debt Instrument, Interest Rate, Stated Percentage pure |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.99B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $1.99B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $1.99B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $1.99B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $1.99B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $1.98B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $1.98B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $1.98B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $1.98B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $1.98B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $1.98B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $1.98B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $1.98B | (m) | (m) | (m) | (m) | (m) | $1.48B | (m) |
| 2023-03-31 | $1.98B | (m) | (m) | (m) | (m) | (m) | $1.52B | (m) |
| 2022-12-31 | $1.98B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $1.44B | (m) |
| 2022-09-30 | $1.98B | (m) | (m) | (m) | (m) | (m) | $1.40B | (m) |
| 2022-06-30 | $1.98B | (m) | (m) | (m) | (m) | (m) | $1.51B | (m) |
| 2022-03-31 | $1.98B | (m) | (m) | (m) | (m) | (m) | $1.69B | (m) |
| 2021-12-31 | $1.98B | (m) | (m) | (m) | (m) | (m) | $1.89B | (m) |
| 2021-09-30 | $1.98B | (m) | (m) | (m) | (m) | (m) | $1.89B | (m) |
| 2021-06-30 | $1.98B | (m) | (m) | (m) | (m) | (m) | $1.87B | (m) |
| 2021-03-31 | $1.98B | (m) | (m) | (m) | (m) | (m) | $1.80B | (m) |
| 2020-12-31 | $1.98B | (m) | (m) | (m) | (m) | (m) | $1.96B | (m) |
| 2020-09-30 | $1.98B | (m) | (m) | (m) | (m) | (m) | $1.93B | (m) |
| 2020-06-30 | (m) | $1.50B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $300.00K | (m) | (m) | $33.10M | (m) | (m) |
| 2015-06-30 | (m) | (m) | $2.00M | (m) | (m) | $33.30M | (m) | (m) |
| 2014-12-31 | (m) | (m) | $7.50M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | $7.50M | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | $400.00M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | $400.00M | (m) | 1.88% |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | $400.00M | (m) | 1.88% |
| 2011-10-31 | (m) | (m) | (m) | (m) | (m) | $400.00M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |